Name of the Issue: Dr. Agarwal's Health Care Limited

1	**Type of Issue**	Initial Public Offer
2	**Issue Size (Rs. Mn)**	30,272.60*

**Source: Basis of Allotment*

3 Grade of issue along with name of the rating agency

Name	Not Applicable
Grade	Not Applicable

4 Subscription Level (Number of times) 1.55

**The above figure is after technical rejection and excludes anchor allotment*
Source: Basis of allotment

5 QIB Holding (as a % of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%
(i) On Allotment *	62.07%
(iii) at the end of 1st FY (March 31, 2025)	65.83%
(iv) at the end of 2nd FY (March 31, 2026)**	N.A.
(v) at the end of 3rd FY (March 31, 2027)**	N.A.

**Shareholding pattern disclosed to Stock Exchanges*

*** QIB Holding not disclosed as reporting for relevant period has not been completed.*

6 Financials of the issuer

(Rs. Million)

Parameters	1st FY (March 31, 2025)	2nd FY (March 31,2026) *	3rd FY (March 31,2027) *
Income from operations	17,110	Not Available	Not Available
Net Profit for the period	1,098	Not Available	Not Available
Paid-up equity share capital	316	Not Available	Not Available
Reserves excluding revaluation reserves	18,350	Not Available	Not Available

** Financials not available as reporting for the relevant years has not been completed.*

7 Trading Status

The equity shares of the Company are listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")
The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2026) *	Not Available
(iii) at the end of 3rd FY (March 31, 2027) *	Not Available

** Trading status not disclosed as the relevant fiscal years have not been completed.*

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2025)	Not Available	Not Available
(ii) at the end of 2nd FY (March 31, 2026) *	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2027) *	Not Available	Not Available

** Changes in Directors of Issuer not updated as the relevant financial years have not been completed*

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document	(i) Repayment/prepayment, in part or full, of certain of our borrowings (INR 1,950.00 mn) (ii) General corporate purposes (INR 774.66 mn)
(ii) Actual utilization	(i) Repayment/prepayment, in part or full, of certain of our borrowings (INR 1950 mn) (ii) General corporate purposes (INR 496.56 mn)
(iii) Reasons for deviation, if any	NA*

**Will be updated once monitoring report is uploaded on the Stock Exchanges website*

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not available*
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not available*
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not available*

**Will be updated once monitoring report is uploaded on the Stock Exchanges website*

12 Pricing Data

Designated Stock Exchange	BSE
Issue Price (Rs.)	402.00
Listing Date	4-Feb-25

Price parameters	At close of listing day- 04-Feb-25	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2025)		
				Closing price	High	Low
Market Price	401.55	405.35	349.60	446.90	463.85	370.10
Sensex	78,583.81	72,989.93	80,796.84	77,414.92	85,978.25	70,234.43

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2026)*			As at the end of the 3rd FY after the listing of the issue (31st March, 2027)*		
	Closing price	High	Low	Closing price	High	Low
Market Price	Not available*	Not available*	Not available*	Not available*	Not available*	Not available*
Sensex	Not available*	Not available*	Not available*	Not available*	Not available*	Not available*

** The pricing data is not disclosed as the relevant fiscal years have not been completed*

13 Basis for Issue Price

Accounting ratio		As disclosed in the Prospectus	At the end of 1st FY (March 31, 2025)	At the end of 1st FY (March 31, 2026)***	At the end of 1st FY (March 31, 2027)***
EPS (Basic)	***Company****	3.14	2.80		
	Peer Group & Industry Avg*		27.30		
	Apollo Hospitals Enterprise Limited	62.50	100.56		
	Max Healthcare Institute Limited	10.89	11.07		
	Fortis Healthcare Limited	7.93	10.26		
	Global Health Limited	17.80	17.92		
	Narayana Hrudayalaya Limited	38.86	38.86		
	Krishna Institute of Medical Sciences Limited	7.75	9.61		
	Aster DM Healthcare Limited	3.60	6.16		
	Rainbow Children's Medicare Limited	21.38	23.97		
EPS (Diluted)	***Company****	3.13	2.78	Not Available	Not Available
	Peer Group & Industry Avg*		27.28	Not Available	Not Available
	Apollo Hospitals Enterprise Limited	62.50	100.56		
	Max Healthcare Institute Limited	10.84	11.01		
	Fortis Healthcare Limited	7.93	10.26		
	Global Health Limited	17.80	17.92		
	Narayana Hrudayalaya Limited	38.86	38.86		
	Krishna Institute of Medical Sciences Limited	7.75	9.61		
	Aster DM Healthcare Limited	3.60	6.16		
	Rainbow Children's Medicare Limited	21.38	23.84		
P/E	***Company****	-	159.14	Not Available	Not Available
	Peer Group & Industry Avg*		68.48	Not Available	Not Available
	Apollo Hospitals Enterprise Limited	107.11	65.85		
	Max Healthcare Institute Limited	95.88	99.61		
	Fortis Healthcare Limited	82.11	68.08		
	Global Health Limited	57.49	66.86		
	Narayana Hrudayalaya Limited	33.14	43.52		
	Krishna Institute of Medical Sciences Limited	79.79	66.52		
	Aster DM Healthcare Limited	136.07	78.70		
	Rainbow Children's Medicare Limited	67.90	58.71		

RONW	***Company****	6.21%	5.88%	Not Available	Not Available
	Peer Group & Industry Avg*		33.66%	Not Available	Not Available
	Apollo Hospitals Enterprise Limited	12.97%	18.25%		
	Max Healthcare Institute Limited	12.58%	11.42%		
	Fortis Healthcare Limited	7.82%	9.04%		
	Global Health Limited	16.46%	14.19%		
	Narayana Hrudayalaya Limited	27.37%	22.73%		
	Krishna Institute of Medical Sciences Limited	16.96%	19.30%		
	Aster DM Healthcare Limited	3.63%	157.69%		
	Rainbow Children's Medicare Limited	17.24%	16.63%		
NAV per share	***Company****	50.53	59.09	Not Available	Not Available
	Peer Group & Industry Avg*		169.49	Not Available	Not Available
	Apollo Hospitals Enterprise Limited	481.93	571.15		
	Max Healthcare Institute Limited	86.54	96.50		
	Fortis Healthcare Limited	101.48	118.11		
	Global Health Limited	108.17	126.08		
	Narayana Hrudayalaya Limited	141.98	177.45		
	Krishna Institute of Medical Sciences Limited	228.47	53.43		
	Aster DM Healthcare Limited	71.62	68.63		
	Rainbow Children's Medicare Limited	124.03	144.58		

Notes

1 All the financial information for listed industry peers is on a consolidated basis and is sourced from the financial information of such listed industry peer as at and for the year ended
2 Shares outstanding are as of September 30, 2024 apart from Narayana Hrudayalaya Limited where shares outstanding are as of December 31, 2024.
3 Subsequent to the year ended March 31, 2024, the effect of stock split has been adjusted retrospectively presented for peers.
4 P/E ratio for the listed industry peers has been computed based on the closing market price of equity shares on BSE Limited ("BSE") as on January 15, 2024 divided by the diluted
5 Return on Net Worth (%) is calculated as profit for the year attributable to the owners of our Company divided by the Net Worth at the end of the respective year.
6 Net asset value (NAV) per equity share (book value per equity share) represents net worth divided by weighted average number of shares as of March 31, 2024.
7 Net worth means aggregate of equity share capital, instruments entirely equity in nature and other equity excluding legal reserve, capital redemption reserve and other amalgamation
8 In the case of Max Healthcare Institute Limited, revenue from operations includes income from other network and partner healthcare facilities, namely Balaji Society, GM Modi Society,
9 Basic and Diluted EPS for Aster DM are for the continuing business operations only.

14 Any other material information

Particulars	Date
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	19-Aug-25
Announcement under Regulation 30 (LODR)-Earnings Call Transcript	16-Aug-25
Announcement under Regulation 30 (LODR)-Monitoring Agency Report	14-Aug-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	12-Aug-25
Unaudited Financial Results For The Quarter Ended June 30, 2025	12-Aug-25
Announcement under Regulation 30 (LODR)-Investor Presentation	12-Aug-25
Board Meeting Outcome for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended	12-Aug-25
Update On Earnings Call For Quarter Ended June 30, 2025	8-Aug-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	6-Aug-25
Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter	30-Jul-25
Announcement under Regulation 30 (LODR)-Credit Rating	30-Jul-25
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	4-Jul-25
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	2-Jul-25
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	2-Jul-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	25-Jun-25
Closure of Trading Window	25-Jun-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	24-Jun-25
Announcement under Regulation 30 (LODR)-Earnings Call Transcript	2-Jun-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	29-May-25
Announcement under Regulation 30 (LODR)-Investor Presentation	29-May-25
Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31, 2025	28-May-25
Commencement Of Operations - New Delhi	27-May-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	24-May-25
Compliances-Reg.24(A)-Annual Secretarial Compliance	21-May-25
Board Meeting Intimation for Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And	20-May-25
Announcement under Regulation 30 (LODR)-Monitoring Agency Report	15-May-25
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	14-May-25
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	21-Apr-25
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	3-Apr-25
Commencement Of Operations Of New Branch - Eluru	27-Mar-25
Closure of Trading Window	27-Mar-25
Commencement Of Operations Of A New Branch - Udhna	24-Mar-25
Commencement Of Operations Of A New Branch - Dombivli	21-Mar-25
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015	17-Mar-25
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015	13-Mar-25
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015	13-Mar-25
Commencement Of Operations Of A New Branch - Gopalpatnam	12-Mar-25
Commencement Of Operations Of A New Branch - Karimnagar	10-Mar-25
Commencement Of Operations Of A New Branch - Virar	8-Mar-25
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	7-Mar-25
Commencement Of Operations Of New Branches - Mysore And Siddipet	6-Mar-25
Commencement Of Operations Of A New Branch - Jaunpur	3-Mar-25
Commencement Of Operations Of A New Branch	27-Feb-25
Commencement Of Operations Of A New Branch	24-Feb-25
Commencement Of Operations Of A New Branch	21-Feb-25
Commencement Of Operation Of A New Branch	19-Feb-25

Announcement under Regulation 30 (LODR)-Credit Rating	17-Feb-25
Integrated Filing (Financial)	15-Feb-25
Outcome Of Board Meeting For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31, 2024	14-Feb-25
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011	14-Feb-25
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results	11-Feb-25
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011	7-Feb-25
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011	6-Feb-25
Listing of Equity Shares of Dr. Agarwals Health Care Ltd	4-Feb-25

Note: For further updates and information, please refer Stock Exchange websites